Related Experiment Video

Updated: May 26, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Non-cardiomyocyte microRNAs in heart failure

Anke J Tijsen1, Yigal M Pinto, Esther E Creemers

  • 1Heart Failure Research Center, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

Cardiovascular Research
|December 20, 2011
PubMed

Insights

MicroRNAs (miRNAs) play a crucial role in heart failure (HF) progression by influencing non-myocyte cells. Understanding miRNA functions in fibroblasts, endothelial, and immune cells is key to novel HF therapies.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • RNA Biology

Background:

  • Heart failure (HF) involves complex structural changes in the myocardium, including myocyte hypertrophy, apoptosis, fibrosis, and altered vascularization.
  • The molecular underpinnings of these myocardial changes are actively investigated, with numerous signaling pathways identified.
  • MicroRNAs (miRNAs), a class of small non-coding RNAs, have recently emerged as critical regulators in cardiac remodeling.

Purpose of the Study:

  • To review the current understanding of miRNA roles in the non-myocyte components of the heart.
  • To elucidate the specific functions of miRNAs in cardiac fibroblasts, endothelial cells, and immune cells during myocardial stress and HF pathogenesis.

Main Methods:

  • Literature review of studies investigating miRNA involvement in cardiac structural changes.
  • Analysis of research focusing on miRNA expression and function in non-myocyte cell types within the heart.
  • Synthesis of findings related to myocardial infarction and heart failure models.

Main Results:

  • miRNAs significantly impact the behavior of cardiac fibroblasts, influencing interstitial fibrosis.
  • Endothelial cell function and capillary density are modulated by specific miRNAs, affecting cardiac vascularization.
  • Immune cell activation and inflammatory responses in the heart are regulated by miRNAs during HF progression.

Conclusions:

  • miRNAs are pivotal regulators of structural remodeling in the failing heart, acting through non-myocyte cell populations.
  • Targeting non-myocyte-specific miRNAs offers a promising therapeutic avenue for treating heart failure.
  • Further research into miRNA mechanisms in cardiac fibroblasts, endothelial cells, and immune cells is essential for developing effective HF interventions.

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...